시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 위장용 일반의약품 시장 보고서(2025년)
Gastrointestinal Over-The-Counter (OTC) Drugs Global Market Report 2025
상품코드 : 1764326
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

위장용 일반의약품 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 시장 성장은 즉각적인 증상 완화 옵션에 대한 수요 증가, 전자상거래 약국 플랫폼의 침투 확대, 병용 OTC 치료제의 가용성 증가, 장내 마이크로바이옴의 주목 고조, 업계 대기업에 의한 마케팅 및 인지 향상 노력의 강화 등에 기인할 것으로 예상됩니다. 기타 요인으로는 프로바이오틱스 기반 OTC 제품의 혁신, 소화기 치료에 포함되는 허브 성분, 정확한 복용 및 휴대성을 위한 포장 개선, 서방형 위장 치료제 개발 등이 있습니다.

위장 질환의 유병률 증가는 향후 수년간 위장용 OTC 의약품 시장의 확대를 촉진할 것으로 예측됩니다. 위장용 OTC 의약품은 위산을 중화하고 장의 기능을 조정하여 증상의 완화에 도움을 줍니다. 또한 위산 과다, 변비, 소화 불량 등 일반적인 문제를 신속하고 간편하게 완화합니다. 2023년 12월, 영국의 IBD Registry Ltd.는 염증성 장 질환(IBD)으로 진단받은 사람의 수가 5,300명을 넘어섰으며 2022년에 비해 3,000명 이상 증가했다고 보고했습니다.

위장용 일반의약품 시장의 주요 기업은 일반의약품(OTC)용 양성자 펌프 억제제(PPI) 등의 선진 제품의 개발을 우선하여 위산과 관련된 증상을 효과적이고 장기적으로 완화하고 있습니다. PPI는 처방전 없이 입수할 수 있는 의약품의 카테고리로 위산의 분비를 억제함으로써 효과를 발휘합니다. 2025년 3월, 일본 제약회사인 Eisai Co., Ltd.는 Pariet S(라베프라졸나트륨 10mg)를 처방약(RX)에서 일반의약품(OTC)으로의 변경 승인을 취득했습니다. 해당 제품은 일본 최초 일반의약품 PPI입니다. Pariet S는 위통, 가슴앓이, 복부 팽만감을 1일 1회 마시기 쉬운 정제로 24시간 동안 완화하는 것으로, 라이프스타일이나 인구 동태의 변화에 따라 위산에 관한 유효한 치료제에 대한 수요가 높아지고 있는 것에 대응하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 팬데믹과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Gastrointestinal over-the-counter (OTC) drugs are non-prescription medications used to prevent or treat common digestive issues. They provide quick and convenient relief for problems like indigestion and irregular bowel movements, helping to effectively manage mild to moderate digestive discomfort and promote overall digestive health in a safe and accessible manner.

The primary categories of gastrointestinal OTC drugs include antacids, laxatives, anti-diarrheals, anti-emetics, and others. Antacids are drugs that work by neutralizing stomach acid to alleviate symptoms such as heartburn and indigestion. These medications are available in different forms, including tablets, capsules, liquids, and more, and are used for various conditions like heartburn, diarrhea, constipation, gastroesophageal reflux disease (GERD), nausea, vomiting, motion sickness, and others. They are distributed through multiple channels such as direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and more, and are utilized by key end-users, including hospitals, clinics, home healthcare, and others.

The gastrointestinal OTC drugs market research report is one of a series of new reports from The Business Research Company that provides gastrointestinal OTC drugs market statistics, including the gastrointestinal OTC drugs industry global market size, regional shares, competitors with the gastrointestinal OTC drugs market share, detailed gastrointestinal OTC drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the gastrointestinal OTC drugs industry. This gastrointestinal OTC drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gastrointestinal over-the-counter (OTC) drugs market size has grown strongly in recent years. It will grow from $45.73 billion in 2024 to $49.59 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to the increasing prevalence of gastrointestinal disorders, growing consumer inclination toward self-medication, expanded availability of OTC proton pump inhibitors, rising awareness of digestive health, and the growing elderly population susceptible to gastrointestinal issues.

The gastrointestinal over-the-counter (OTC) drugs market size is expected to see strong growth in the next few years. It will grow to $67.88 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to the rising demand for fast-acting symptom relief options, greater penetration of e-commerce pharmacy platforms, increased availability of combination OTC treatments, growing emphasis on gut microbiome health, and intensified marketing and awareness efforts by major industry players. Key trends anticipated during the forecast period include advancements in the formulation of quick-acting antacids, innovation in probiotic-based OTC products, incorporation of herbal ingredients into digestive treatments, improvements in packaging for accurate dosing and portability, and the development of sustained-release gastrointestinal therapies.

The growing prevalence of digestive disorders is expected to drive the expansion of the gastrointestinal OTC drugs market in the coming years. Digestive disorders encompass various conditions affecting the gastrointestinal tract, including the stomach, intestines, and related organs. This rise in digestive issues is primarily linked to increased consumption of processed, low-fiber foods, which negatively impact gut health and digestion. Gastrointestinal OTC medications help alleviate symptoms by neutralizing stomach acid, regulating bowel function, and supporting gut health. They offer quick and convenient relief for common problems such as acidity, constipation, and indigestion. For example, in December 2023, IBD Registry Ltd., a UK-based non-profit organization, reported that the number of individuals diagnosed with inflammatory bowel disease (IBD) surpassed 5,300, representing a rise of over 3,000 compared to 2022. Thus, the increasing occurrence of digestive disorders is fueling the growth of the gastrointestinal OTC drugs market.

Leading companies in the gastrointestinal OTC drugs market are prioritizing the development of advanced products, such as over-the-counter (OTC) proton pump inhibitors (PPIs), to deliver effective and long-lasting relief from acid-related conditions. OTC PPIs are a category of medications available without a prescription that work by reducing stomach acid production. They are frequently used to manage ailments like frequent heartburn, acid reflux (GERD), and gastric ulcers. For example, in March 2025, Eisai Co., Ltd., a pharmaceutical company based in Japan, received approval to convert its Pariet S (rabeprazole sodium 10 mg) from a prescription (RX) to an over-the-counter (OTC) medication. This marked the first OTC PPI in Japan containing the same active ingredient and dosage as its prescription counterpart. Pariet S is used to treat stomach pain, heartburn, and bloating, offering 24-hour relief through a once-daily, easy-to-swallow tablet, and is designed to meet the increasing demand for effective gastric acid-related therapies prompted by lifestyle and demographic changes.

In June 2022, Glenmark Pharmaceuticals Ltd., a pharmaceutical company based in the U.S., acquired select OTC medications from Wockhardt Ltd. for an undisclosed amount. This acquisition is intended to strengthen Glenmark's OTC product portfolio in the U.S. market, with a particular focus on the gastrointestinal segment. Wockhardt Limited, also based in the U.S., is a pharmaceutical company that produces gastrointestinal OTC drugs.

Major players in the gastrointestinal over-the-counter (otc) drugs market are Pfizer Inc., Procter & Gamble Co., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Reckitt Benckiser Group plc, Boehringer Ingelheim GmbH, Haleon plc, Sandoz AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Dr. Reddy's Laboratories Ltd.

North America was the largest region in the gastrointestinal over-the-counter (OTC) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastrointestinal over-the-counter (OTC) drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastrointestinal over-the-counter (OTC) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastrointestinal over-the-counter (OTC) drugs market consists of sales of digestive enzymes, probiotics, stool softeners, and fiber supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastrointestinal Over-The-Counter (OTC) Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastrointestinal over-the-counter (otc) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for gastrointestinal over-the-counter (otc) drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastrointestinal over-the-counter (otc) drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Gastrointestinal Over-The-Counter (OTC) Drugs Market Characteristics

3. Gastrointestinal Over-The-Counter (OTC) Drugs Market Trends And Strategies

4. Gastrointestinal Over-The-Counter (OTC) Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gastrointestinal Over-The-Counter (OTC) Drugs Growth Analysis And Strategic Analysis Framework

6. Gastrointestinal Over-The-Counter (OTC) Drugs Market Segmentation

7. Gastrointestinal Over-The-Counter (OTC) Drugs Market Regional And Country Analysis

8. Asia-Pacific Gastrointestinal Over-The-Counter (OTC) Drugs Market

9. China Gastrointestinal Over-The-Counter (OTC) Drugs Market

10. India Gastrointestinal Over-The-Counter (OTC) Drugs Market

11. Japan Gastrointestinal Over-The-Counter (OTC) Drugs Market

12. Australia Gastrointestinal Over-The-Counter (OTC) Drugs Market

13. Indonesia Gastrointestinal Over-The-Counter (OTC) Drugs Market

14. South Korea Gastrointestinal Over-The-Counter (OTC) Drugs Market

15. Western Europe Gastrointestinal Over-The-Counter (OTC) Drugs Market

16. UK Gastrointestinal Over-The-Counter (OTC) Drugs Market

17. Germany Gastrointestinal Over-The-Counter (OTC) Drugs Market

18. France Gastrointestinal Over-The-Counter (OTC) Drugs Market

19. Italy Gastrointestinal Over-The-Counter (OTC) Drugs Market

20. Spain Gastrointestinal Over-The-Counter (OTC) Drugs Market

21. Eastern Europe Gastrointestinal Over-The-Counter (OTC) Drugs Market

22. Russia Gastrointestinal Over-The-Counter (OTC) Drugs Market

23. North America Gastrointestinal Over-The-Counter (OTC) Drugs Market

24. USA Gastrointestinal Over-The-Counter (OTC) Drugs Market

25. Canada Gastrointestinal Over-The-Counter (OTC) Drugs Market

26. South America Gastrointestinal Over-The-Counter (OTC) Drugs Market

27. Brazil Gastrointestinal Over-The-Counter (OTC) Drugs Market

28. Middle East Gastrointestinal Over-The-Counter (OTC) Drugs Market

29. Africa Gastrointestinal Over-The-Counter (OTC) Drugs Market

30. Gastrointestinal Over-The-Counter (OTC) Drugs Market Competitive Landscape And Company Profiles

31. Gastrointestinal Over-The-Counter (OTC) Drugs Market Other Major And Innovative Companies

32. Global Gastrointestinal Over-The-Counter (OTC) Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastrointestinal Over-The-Counter (OTC) Drugs Market

34. Recent Developments In The Gastrointestinal Over-The-Counter (OTC) Drugs Market

35. Gastrointestinal Over-The-Counter (OTC) Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기